Tong · Aging 2024 · Computational biomarker development and validation study · n=?

Cell-type specific epigenetic clocks to quantify biological age at cell-type resolution.

Cited 30 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Bench/computational biomarker development and cross-sectional tissue methylation analysis without clinical trial or prospective cohort design

PubMed 39760516 · doi:10.18632/aging.206184 · record verified 2026-08-30

What was done

The authors quantified the contribution of cell composition shifts versus cell-intrinsic aging to bulk tissue epigenetic clocks in blood and brain. Using brain and liver datasets, they developed and validated neuron-, glia-, and hepatocyte-specific DNA methylation clocks. They evaluated these cell-type-specific clocks against non-cell-type-specific clocks in the context of Alzheimer's disease (specifically looking at temporal lobe neurons and glia) and various liver pathologies.

What was found

Underlying shifts in cell subsets accounted for approximately 39% (lymphocyte subsets in blood) and 12% (neuronal subsets in brain) of standard epigenetic clock accuracy. Neuron- and glia-specific clocks demonstrated biological age acceleration in Alzheimer's disease, with the strongest effect observed in temporal lobe glia, whereas non-cell-type-specific clocks showed marginal or no acceleration. Clock CpGs showed a significant overlap with the causal DamAge clock and mapped to neurodegeneration-related genes. The hepatocyte-specific clock demonstrated accelerated biological aging under pathological liver conditions. Exact sample sizes, correlation coefficients, and effect sizes were not reported in the abstract.

Why it matters

Standard bulk-tissue epigenetic clocks conflate changes in cell proportion with intracellular aging. Establishing cell-type-resolved DNA methylation clocks clarifies the biological mechanisms of tissue aging and enhances sensitivity for detecting accelerated aging in neurodegenerative and organ-specific diseases.

Limits

The abstract does not disclose sample sizes (n), demographic details, tissue donor characteristics, or specific performance metrics (e.g., median absolute error, correlation coefficients, or p-values). Validation across independent, diverse external cohorts and functional experimental verification were not detailed in the abstract.

Cited by